ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,930.14
-0.02%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) Noticias

IFRX

InflaRx NV (IFRX)

InflaRx NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IFRX
FechaHoraFuenteTítuloSímboloCompañía
08/05/202407:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
08/05/202406:30GlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
30/04/202406:30GlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
24/04/202406:30GlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
21/03/202406:00GlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
19/03/202406:30GlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
22/02/202406:30GlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
25/01/202406:30GlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
04/01/202406:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
06/11/202306:30GlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
01/11/202306:30GlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
11/09/202306:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
30/08/202306:30GlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
10/08/202306:30GlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
12/07/202315:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
11/07/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
30/06/202315:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
28/06/202307:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
28/06/202306:30GlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
21/06/202306:00GlobeNewswire Inc.InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
11/05/202306:30GlobeNewswire Inc.InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
24/04/202315:48Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:IFRXInflaRx NV
18/04/202315:01GlobeNewswire Inc.InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionNASDAQ:IFRXInflaRx NV
14/04/202315:01GlobeNewswire Inc.InflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
13/04/202307:48Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IFRXInflaRx NV
11/04/202320:08GlobeNewswire Inc.InflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
11/04/202315:00GlobeNewswire Inc.InflaRx Announces Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
05/04/202310:30Dow Jones NewsInflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19NASDAQ:IFRXInflaRx NV
04/04/202314:42Dow Jones NewsInflaRx's Gohibic Gets Emergency Use Authorization from FDA for Covid-19 Hospitalized PatientsNASDAQ:IFRXInflaRx NV
04/04/202313:55GlobeNewswire Inc.InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
 Showing the most relevant articles for your search:NASDAQ:IFRX

Su Consulta Reciente

BITMOT
844834
Romania Tf 2,375% Ap27 Eur
USOTC
SCNLF
Scancell (PK)
NASDAQ
FNBSRX
International Capital St...
NYSE
ODY
BIT
P1KP43
BNP Paribas Issuance
AMEX
BCM
iPath Pure Beta Broad Co...
AMEX
LEWY
LeeWay Services
KOSPI
317400
Xi S and D
DBI
DH58
Leverage DAX X6 Total Re...
TG
MPV
Meid Bank Private
NYSE
CIV-CL
XE
IOS
IONOS
AMEX
NTSI
Wisdomtree International...
LSE
91SA
Nationwde. 25
BINA
LUNABTC
NEO
FCIM
Fidelity International M...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados